Oppenheimer Reiterates Outperform Rating for Ascendis Pharma A/S (NASDAQ:ASND)
Oppenheimer reissued their outperform rating on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a research note published on Tuesday morning, Benzinga reports. They currently have a $190.00 price objective on the biotechnology company’s stock, up from their prior price objective of $180.00. ASND has been the subject of several other reports. The […]
21 Sep 06:58 · The Markets Daily